Overview

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Status:
RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

Cryosurgery
lenvatinib